SEC Won't Take Action Against Ocular Over Eye Drug
Two days after defeating a proposed class action claiming it misled investors about federal approval for an eye pain reliever, Massachusetts-based Ocular Therapeutix learned the U.S. Securities and Exchange Commission would...To view the full article, register now.
Already a subscriber? Click here to view full article